iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.
about
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agentsAltered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivoGlycolipid activators of invariant NKT cells as vaccine adjuvants.Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015.Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
P2860
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
iNKT/CD1d-antitumor immunother ...... /peptide-based cancer vaccine.
@en
iNKT/CD1d-antitumor immunother ...... /peptide-based cancer vaccine.
@nl
type
label
iNKT/CD1d-antitumor immunother ...... /peptide-based cancer vaccine.
@en
iNKT/CD1d-antitumor immunother ...... /peptide-based cancer vaccine.
@nl
prefLabel
iNKT/CD1d-antitumor immunother ...... /peptide-based cancer vaccine.
@en
iNKT/CD1d-antitumor immunother ...... /peptide-based cancer vaccine.
@nl
P2093
P2860
P1476
iNKT/CD1d-antitumor immunother ...... /peptide-based cancer vaccine.
@en
P2093
Alena Donda
Jean-Pierre Mach
Lianjun Zhang
Pedro Romero
P2860
P2888
P356
10.1186/S40425-014-0039-8
P577
2014-11-18T00:00:00Z
P5875
P6179
1053625714